Genomma Lab Internacional Sab De Cv Class B · BMV:LAB/B
Genomma Lab Internacional Sab De Cv Class B — Q2 2025 Earnings Presentation
33 slides from Genomma Lab Internacional Sab De Cv Class B's earnings presentation, July 2025
Slide 1: Genomma Lab Internacional Investor Relations
Genomma Lab.°® Internacional GENOMMA LAB INVESTOR RELATIONS
Slide 2: Forward-looking statements disclaimer
This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limit
Slide 3: Slide 3
Slide 4: About Genomma Lab
ABOUT GENOMMA LAB GENOMMA LAB pevetops, MANUFACTURES AND MARKETS 4 PORTFOLIO OF 60 PREMIUM BRANDED PRODUCTS FOR MASS CONSUMPTION, MANY OF WHICH ARE LEADERS IN THEIR CATEGORIES BUSINESS UNITS REGIONS 43% 51% 33% 47% aed ore 2S MEXICO », 6% A BEVERAGES 10% us
Slide 5: Healthy Product Mix: Over-the-Counter Medicines
HEALTHY PRODUCT MIX OVER-THE-COUNTER MEDICINES COUGH & COLD ANALGESICS DERMA OTC
Slide 6: Healthy Product Mix: Personal Care
HEALTHY PRODUCT MIX PERSONAL CARE SKINCARE HAIRCARE ( Ver = Fy od ile OTHER
Slide 7: Healthy Product Mix: Beverages
HEALTHY PRODUCT MIX BEVERAGES yw * . y } Siierc. SUER(, SUEROX ‘UcROX)SUERO “SUEROX;SUERO oRMULAHIDRATA FORMULAHIDRATANTE OR
Slide 8: Proven Track Record
Slide 9: Net Sales and EBITDA in MXN million
Net Sales in MXN million EBITDA in MXN million net of discontinued operation effects
Slide 10: Maintaining Gross Margin with Productivity
MANTAINING GROSS MARGIN WITH PRODUCTIVITY 56.9% Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 @4 2024 Q1 2025 Q2 2025
Slide 11: Net of discontinued operation effects
Net of discontinued operation effects
Slide 12: $2.1 $1.9 $1.7 $1.5 $1.3 $1.1 $0.9 $0.7 $0.5 0
$2.1 0 $1.9 0 $1.7 0 $1.5 0 $1.3 0 $1.1 0 $0.9 0 $0.7 0 $0.5 0
Slide 13: Free Cash Flow and Dividend per Share
Free Cash Flow in MXN million, Dividend per Share in MXN
Slide 14: Cash Conversion Cycle
CASH CONVERSION CYCLE 122 117 116 "5 . . Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 FIGURES IN DAYS
Slide 15: 17. 0% 16. 0% 15. 0% 14. 0% 13. 0% 12. 0% 11. 0%
17. 0% 16. 0% 15. 0% 14. 0% 13. 0% 12. 0% 11. 0% 10. 0%
Slide 16: MXN 1,800 M progress
MXN 1,800 M 180 0 1600 160 0 140 0 1200 120 0 100 0 800 800 MXN 1,018 M 600 57% of progress 400 400 200 0 0 2022 2023 2024 2025 2026 2027
Slide 17: Capital Allocation Priorities
CAPITAL ALLOCATION PRIORITIES 1. INVEST IN THE CORE BUSINESS $500 million 2025 year-end CAPEX: ¢ New Suerox production line commissioning ¢ New plastics plant comissioning ¢ Central warehouse expansion 2. TOTAL SHAREHOLDER RETURN $800 million annual dividend priority Strategic buybacks
Slide 18: 2025 outlook
• Near-zero growth • 24% average • Q3 2025 worst expected quarter of the year with a single-digit contraction • Strong FX headwinds in 2H 2025 • Gradual path to • 24% average • New routes opened double-digit growth • Advancing product relaunches • On going productivity
Slide 19: The Future Is Bright
Slide 20: 25,0 20,0 15,0 10,0 5,00 -
25,0 00 20,0 00 15,0 00 10,0 00 5,00 0 -
Slide 21: There Is More to Conquer
THERE IS MORE TO CONQUER OUR GROWING MARKET SHARES HAVE A HUGE POTENTIAL Beverages Personal Care oTCc Including Brazil Infant Nutrition SHARE OF MARKET Mexico + Latam 5.3% 2.8% 8.2% 5.3% 1.4% CATEGORY SIZE Mexico + Latam US$ 2.4 billion US$ 10.5 billion US$ 4.9 billion US$8.0 billion US$ 24 billion
Slide 22: Our Strategic Edge
OUR STRATEGIC EDGE THE NEW STAGE OF THE COMPANY 1. ICONIC PRODUCTS 2. SPEED TO MARKET 3. IMPECABLE EXECUTION
Slide 23: Brand relaunch initiatives by business unit
BU Brand Better Fresh Increased Expanded New New New New International Formula design routine use /demo forms functions sizes category Roll-out Skincare CICA ✓ ✓ ✓ ✓ ✓ ✓ TTCAL ✓ ✓ ✓ ✓ ✓ ✓ ✓ ASPX ✓ ✓ ✓ ✓ ✓ ✓ ✓ Haircare TN ✓ ✓ ✓ ✓ ✓ ✓ ✓ VRT ✓ ✓ ✓ ✓ OTC C&C ✓ ✓ ✓ ✓ ✓ ANLG ✓ ✓ ✓ ✓ ✓ GASTR ✓ ✓ ✓ ✓ ✓ ✓ DE
Slide 24: Asepxia Relaunch
ASEPXIA RELAUNCH 4 NS NNN Improved formula Hydrating serum + salicylic acid Fresh Design Expanded use From facial acne treatment to full-body daily care Speed to market 7 months from development to execution Impecable execution Moved from pharmacy to general sopa isle Expanded shelf presence Strong
Slide 25: Asepxia Relaunch Progressing in Mexico
ASEPXIA RELAUNCH PROGRESSING IN MEXICO Asepxia soap bars: Mexico sell-out Weekly data
Slide 26: Strengthening OTC Innovation Pipeline
STREGTHENING OTC INNOVATION PIPELINE STRONG OTC REGISTRIES MOMENTUM: SUBMITTED REGISTRIES SINCE 2023 NOW APPROACHING APPROVAL STAGE Submitted OTC registries 98 ' 2022 2023 2024 126
Slide 27: Q2 2025 Overview
Slide 28: Q2 2025 key metrics
0.5% +5.5% (ex ARG) 0.3% 23.8% +89bps 355.0 M -43.8% 667.8 M +16.6% 0.35 -43.8% 115 d -7 d -10d Inventories - 4d Clients 2,705 M +64.6% 67% 75%
Slide 29: Suerox sales and temperature by week
27.4 27.1 26.9 26.4 26.4 26.5 50 25 24.7 24.9 24.7 24.5 24.4 24.6 24.3 45 23.8 23.8 40 22.9 23.1 22.8 22.8 22.5 22.3 35 22 30 20.1 25 20 15 10 5 0 week week week week week week week week week week week week week week week week week week week week week week week week week week 1 2 3 4 5 6 7 8 9 10 11
Slide 30: Expanding Suerox Distribution in Mexico
EXPANDING SUEROX DISTRIBUTION IN MEXICO OPENED NEW TRADITIONAL CHANNEL ROUTS IN NORTHWESTERN MEXICAN REGION WITH ACCESS TO HIGHER TEMPERATURES Latam traditional channel sales Data in US$ Million Excluding US 30 $163 New routes in Mexico $123 120 Mexico route openings $87 so $84 12-month target 61 62
Slide 31: Q2 2025 YTD Portfolio Performance
Q2 2025 YTD PORTFOLIO PERFORMANCE 67% OF SALES GROWING OR MAINTAINING SHARE *Data in MXN OVER-THE-COUNTER PERSONAL CARE BEVERAGES INFANT NUTRITION 20%
Slide 32: Q2 2025 YTD Market Performance
Q2 2025 YTD MARKET PERFORMANCE 75% OF SALES GROWING ABOVE INFLATION *Data in Local Currency 20%
Slide 33: Genomma Lab
Genomma Lab.°® GENOMMA LAB
Genomma Lab Internacional — Q2 2025 Earnings Presentation on 6ix